Journal
CURRENT PSYCHIATRY REPORTS
Volume 16, Issue 10, Pages -Publisher
SPRINGER
DOI: 10.1007/s11920-014-0473-9
Keywords
Pharmacogenetics; Antipsychotics; Weight gain; Clozapine; Olanzapine; Epigenetics; Serumlevels; Biomarkers
Categories
Funding
- Brain & Behaviour Research Foundation Independent Investigator Award
- Canadian Institutes of Health Research Operating Funds [MOP 89853]
- Canadian Institutes of Health Research Michael Smith New Investigator Salary Prize for Research in Schizophrenia
- Early Researcher Award by the Ministry of Research and Innovation of Ontario
Ask authors/readers for more resources
Antipsychotic-induced weight gain (AIWG) is a prevalent side effect of antipsychotic treatment, particularly with second generation antipsychotics, such as clozapine and olanzapine. At this point, there is virtually nothing that can be done to predict who will be affected by AIWG. However, hope for the future of prediction lies with genetic risk factors. Many genes have been studied for their association with AIWG with a variety of promising findings. This review will focus on genetic findings in the last year and will discuss the first epigenetic and biomarker findings as well. Although there are significant findings in many other genes, the most consistently replicated findings are in the melanocortin 4 receptor (MC4R), the serotonin 2C receptor (HTR2C), the leptin, the neuropeptide Y (NPY) and the cannabinoid receptor 1 (CNR1) genes. The study of genetic risk variants poses great promise in creating predictive tools for side effects such as AIWG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available